The significant challenge in unwinding custom OTC derivatives is that the original counterparty may leverage their exclusive position to demand unfavorable terms, including a premium. The bespoke nature of these derivatives means they are not fungible, making it difficult to find alternative counterparties or to transfer them in the open market. Therefore, clients may face unfavorable conditions or premiums imposed by the original counterparty when trying to unwind or alter these positions.

A is incorrect because unwinding custom OTC derivatives is typically more complex than standardized products due to their lack of fungibility and the need to negotiate with the original counterparty.

C is incorrect because custom OTC derivatives generally cannot be transferred to a third party without the original counterparty’s consent, due to their bespoke nature and lack of a standardized market.

D is incorrect because the market for custom OTC derivatives is typically less liquid compared to standardized derivatives, making it more challenging to unwind these positions at fair market value.

Things to Remember

• The non-fungibility of custom OTC derivatives often leads to a dependency on the original counterparty for unwinding, who may impose unfavorable conditions.
• This lack of flexibility and potential for unfavorable terms from the original counterparty needs to be carefully considered when entering into custom OTC derivatives contracts.
• Risk managers should be aware of these challenges and factor them into their risk assessment and mitigation strategies for derivative portfolios.